InflaRx (IFRX) EV/EBIT: History & Chart

InflaRx N.V.(IFRX)

Biotechnology · Jena, TH

$1.59-0.09 (-5.36%)

Delayed quote: Oct 6, 2026, 1:44 PM EDT

About InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.

Jena, TH

65 employees

www.inflarx.de

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Niels C. Riedemann

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
InflaRx N.V. (IFRX)	$234.20M	N/A	N/A	N/A	N/A
BioAge Labs Inc. (BIOA)vs ›	$233.05M	N/A	N/A	N/A	N/A
Nautilus Biotechnolgy, Inc. (NAUT)vs ›	$232.88M	N/A	N/A	N/A	N/A
Utah Medical Products, Inc. (UTMD)vs ›	$235.79M	22.97x	12.07x	10.11x	11.81x
Akebia Therapeutics, Inc. (AKBA)vs ›	$236.23M	N/A	245.87x	245.87x	245.87x
SIGA Technologies, Inc. (SIGA)vs ›	$236.33M	N/A	5.15x	5.03x	6.70x
MacroGenics, Inc. (MGNX)vs ›	$231.75M	N/A	378.61x	334476.42x	334476.42x
High Tide Inc. (HITI)vs ›	$236.81M	99.14x	177.33x	172.45x	172.45x
Invivyd, Inc. (IVVD)vs ›	$237.31M	N/A	N/A	N/A	N/A
Q32 Bio Inc. (QTTB)vs ›	$238.56M	6.41x	4.53x	4.53x	4.53x

NAME

MARKET CAP

EV/EBIT RATIO

TTM

InflaRx N.V. (IFRX)

$234.20M

N/A

BioAge Labs Inc. (BIOA)vs ›

$233.05M

N/A

Nautilus Biotechnolgy, Inc. (NAUT)vs ›

$232.88M